neovascular Age-Related Macular Degeneration | News Search

跳至主要内容

MedPath Trial Home

机构资讯 AI 研究

数据来源：ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

搜索试验。追踪管线。洞察审批。由 AI 驱动的临床研究情报平台。

产品

临床试验
药物情报
全球审批
深度研究
价格方案

资源

常见问题
搜索

公司

资讯
关于我们
联系我们

法律

隐私政策
服务条款

免责声明： 本网站提供信息检索和数据分析服务。内容不构成医疗建议。适应性评估仅供参考，不能替代合格医疗专业人员的咨询。数据来源于公共注册库和监管机构；MedPath 不保证数据的完整性或准确性。请以原始资料为准。

© 2026 MedPath Trial 版权所有

服务条款隐私政策

我们重视您的隐私

我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。

找到 64,290 条关于 “neovascular Age-Related Macular Degeneration”

Faricimab Demonstrates Efficacy in Treatment-Naïve Neovascular AMD Patients

ABBV-RGX-314 Gene Therapy Shows Promise in Bilateral Neovascular AMD

Merck Initiates Pivotal Phase 2b/3 Trial for Novel Bispecific Antibody MK-8748 in Wet Age-Related Macular Degeneration

Proteomic Analysis Reveals Molecular Changes Following Anti-VEGF Therapy in Age-Related Macular Degeneration

European Commission Approves Sandoz's Afqlir® (aflibercept) Biosimilar for Retinal Diseases

Kalaris Therapeutics to Present First-in-Human Data for Novel Dual-Targeting AMD Therapy TH103

European Commission Approves Sandoz's Afqlir, an Aflibercept Biosimilar, for Retinal Diseases

Kexing Biopharm Doses First Subject in Phase I Trial of Bispecific Antibody GB10 for Neovascular AMD

Sylentis Reports Positive Phase IIa Results for SYL1801 Eye Drops in Age-Related Macular Degeneration

Real-World Study Confirms Safety and Efficacy of Aflibercept Biosimilar Pavblu in 6,313 Patients

第 1 页，共 1376 页